Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2647 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-25 (mundorh.com.br)
From sabbatical to flexible journeys: global strategies to balance work and quality of life -
Find out how companies around the world are adopting strategies such as four-day week, sabbatical periods and flexible journeys to increase productivity and improve employees' welfare
Read more
2025-02-03 (panoramafarmaceutico.com.br)
Biogen has a new HEAD of Human Resources
Priscila Damiani is the new HEAD of Human Resources for Brazil in Biogen, a multinational pharmacist of American origin. With 26 years of experience, the
Read more
2024-11-09 (notretemps.com)
Charcot: a potential treatment being evaluated for reimbursement
The High Authority for Health (HAS) indicated on Friday that it was continuing to evaluate the eligibility for reimbursement of a treatment for a rare form of Charcot disease which it recently refused to make available before its official marketing, at much to the chagrin of patients. In...
Read more
2024-11-09 (whatsupdoc-lemag.fr)
Charcot disease: Finally, the HAS does not exclude the reimbursement of Qalsody, a “hopeful” treatment for certain patients
Charcot's disease: Finally, the HAS does not exclude the reimbursement of Qalsody, a "hopeful" treatment for certain patients - The High Authority for Health (HAS) has indicated that it is continuing to evaluate the eligibility for reimbursement of a treatment of a rare form of Charcot disease that she refused
Read more
2024-11-03 (la-croix.com)
Charcot disease: France refuses early access to a promising treatment
On October 22, the High Authority for Health refused early access to Qalsody, a treatment developed by Biogen against a rare form of Charcot disease. An “unacceptable” decision for the ARSLA patients association, which is waiting for the HAS to reverse its decision during an appeal...
Read more
2024-10-15 (femtechinsider.com)
Talkiatry Partners with Biogen; Expands Virtual Postpartum Depression Care Services
Talkiatry, a provider of in-network psychiatric care, has announced the expansion of its services to include virtual postpartum depression (PPD) care. This new initiative aims to improve access to mental health support for women experiencing...
Read more
2024-10-01 (technologynetworks.com)
The Evolving Treatment Landscape for Alzheimer’s
Explore the latest advances in Alzheimer's treatments, from novel drug therapies to emerging research, reshaping the future of care for patients.
Read more
2024-09-18 (limerickleader.ie)
Limerick man named new president of Irish Pharmaceutical Healthcare Association
The organisation also launched its General Election Manifesto bringing forward innovative ideas on how patients in Ireland can have faster access to new medici...
Read more
2024-08-27 (fingerlakes1.com)
The Best of Boston: A Guide to Senior Living in 2024
The Best of Boston: A Guide to Senior Living in 2024 Travel
Read more